Articles by Dr. Yuki Tanaka
Lunai Bioworks Raises $20 Million to Acquire CNS Drug Delivery Technology for Alzheimer's Treatment
Lunai Bioworks completes $20M preferred equity raise to acquire CNS delivery tech and neurotherapeutic IP, expanding Alzheimer's disease treatment platform.
ANVISA Approves New Cannabis Framework & MagicTouch Device: Market Impact
The recent ANVISA approval of a new cannabis framework and the MagicTouch device marks a significant advancement in pain management solutions in Brazil.
Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Era
Purdue Pharma, the manufacturer of OxyContin, is ceasing operations as part of a $7.4 billion settlement to resolve claims related to the opioid crisis. This landmark deal signifies a major turning point in the legal and societal reckoning with the epidemic.
Auvelity FDA Approval: A New MDD Treatment Option
The FDA has approved Auvelity, a novel oral therapy from Axsome Therapeutics, for the treatment of major depressive disorder (MDD). This marks a significant advancement in MDD treatment options.
TGA Issues Guidance on Combination and Boundary Products for Pharmaceutical Companies in APAC
Australia's TGA provides regulatory clarity on combination products like pre-filled syringes and boundary products including nasal decongestants.
EU Pharmaceutical Legislation Reform: Impact on Orphan Drug Market Exclusivity
This article examines how recent EU pharmaceutical legislation reforms could reshape market exclusivity for orphan drugs, affecting access to treatments for rare diseases.
ChinaBio Partnering Forum 2026: Key Takeaways and Highlights
The ChinaBio® Partnering Forum 2026 concluded April 29 in Shanghai, with panelists highlighting Ledger Run's ClinRun platform for automating clinical trial payments. While comprehensive post-event reporting remains limited, the hybrid event positioned Chinese biotechs at a critical dealmaking inflection point.
ChinaBio Partnering Forum: Biotech Deals & APAC Innovation
The ChinaBio® Partnering Forum catalyzes biotech deal-making and innovation across Asia-Pacific, with emerging focus on AI-driven drug discovery, cell and gene therapies, and regulatory harmonization reshaping the competitive landscape.
European Pediatric Investigation Plans: Accelerating Oncology Drug Development Timelines
European Pediatric Investigation Plans are crucial for expediting oncology drug development, ensuring timely access to innovative treatments for pediatric cancer patients.
NMPA Accelerated Approval Pathway: What Foreign Pharma Must Know
The NMPA Accelerated Approval Pathway offers foreign pharmaceutical companies a streamlined route to market for drugs like XYZ, enhancing patient access to vital therapies.
Clinical Trial Regulatory Harmonization: NMPA & PMDA ICH Adoption in APAC
This article delves into the regulatory harmonization of clinical trials in APAC, focusing on NMPA and PMDA's ICH adoption to expedite drug approvals.
Rare Disease Clinical Trials LATAM: Regulatory Incentives & Patient Access
This article delves into the regulatory landscape of rare disease clinical trials in LATAM, highlighting incentives that improve patient access to essential therapies.
ChinaBio Partnering Forum: Biotech Deals & Investment Insights
The ChinaBio® Partnering Forum convenes Asia-Pacific biotech stakeholders to explore investment opportunities, cross-border partnerships, and emerging therapeutic innovations. The forum facilitates deal-making and strategic collaboration across the dynamic APAC biotech ecosystem.
ChinaBio Partnering Forum: Biotech Investment Trends Emerge
The ChinaBio® Partnering Forum convened industry leaders to assess biotech investment trends and partnership opportunities across Asia-Pacific. Regulatory reforms, emerging technologies, and strategic cross-border collaborations are reshaping the investment landscape.
Evofem Biosciences Secures Exclusive SOLOSEC Distribution Agreement for Sub-Saharan Africa Market
Evofem Biosciences announces exclusive distribution deal for SOLOSEC (secnidazole) in Sub-Saharan Africa, expanding access to FDA-approved treatment.
Australia's TGA Updates Personalised Medical Device Regulations: New Guidance for Market Authorization and Supply Chain Compliance
Australia's TGA releases comprehensive regulatory guidance for personalised medical devices, covering application processes, market authorization, and supply chain requirements.
Australia's TGA Updates Comprehensive Biologicals Regulatory Framework for Advanced Therapies
Australia's TGA provides updated guidance on biologicals regulation including blood products, tissues, and advanced therapies under ARGB framework.
The Market for Monoclonal Antibodies: Trends, Challenges, and Opportunities
This study analyzes the monoclonal antibody market, focusing on patent activity, pricing, and market concentration.
EU Pharmaceutical Legislation Impact: Biosimilar Market Entry & Competition 2027
This article examines how upcoming EU pharmaceutical legislation will influence the biosimilar market, focusing on Adalimumab and competition dynamics by 2027.
EU Pharmaceutical Legislation Reform: Impact on Orphan Drugs & Market Exclusivity
This article delves into the EU pharmaceutical legislation reform and its implications for orphan drugs, focusing on market exclusivity and patient access.